We chose the combination of MELK (OTS167) and CDK (RGB-286638) inhibitors because 1) ACC overexpressed MELK, CDK1, CDK2, and partnering cyclins, and 2) these therapeutic targets of OTS167 and RGB-286638 were associated with advanced ACC and independently associated with shorter OS and DFS in several databases, suggesting their role in ACC progression [10]. The gene discussed is MELK; the disease is adrenal cortex carcinoma.